Skip to main content
SpringerLink
Log in

Das Nierenzellkarzinom

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Seit seiner Entdeckung vor 165 Jahren haben sich sowohl in der Diagnostik als auch in der Therapie des Nierenzellkarzinoms große Fortschritte bemerkbar gemacht. Während zunächst eine Standardisierung der Operationstechnik zu einer deutlich verbesserten Langzeitprognose der Patienten führte, sorgte die Einführung von Sonographie, Computertomographie (CT) und Magnetresonanztomographie (MRT) dafür, dass vermehrt kleine inzidentelle Karzinome detektiert wurden, was wiederum in einer besseren Prognose resultierte. Neuere Operationstechniken wie die organerhaltende Tumorresektion oder minimal-invasive Verfahren führten zu weiteren Verbesserungen der operativen Therapie. Beim metastasierten Nierenzellkarzinom stellt die Immuntherapie mit Zytokinen eine wichtige Säule zur Behandlung der Patienten dar. Neue Substanzen, die Faktoren für Tumorzellwachstum und Angiogenese inhibieren, eröffnen neue Therapieansätze, die sich in den nächsten Jahren verstärkt durchsetzen werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Alamdari FI, Ljungberg B (2005) Adrenal metastasis in renal cell carcinoma: a recommendation for adjustment of the TNM staging system. Scand J Urol Nephrol 39: 277–282

    Article  PubMed  Google Scholar 

  2. Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 227: 177–186

    Google Scholar 

  3. Amin MB, Corless CL, Renshaw AA et al. (1997) Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 21: 621–635

    Article  PubMed  Google Scholar 

  4. Amin MB, Tamboli P, Javidan J et al. (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26: 281–291

    Article  PubMed  Google Scholar 

  5. Argani P, Antonescu CR, Illei PB et al. (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma. A distinctive tumor entity previously included among renal cell carcinoma of children and adolescents. Am J Pathol 159: 179–192

    PubMed  Google Scholar 

  6. Argani P, Antonescu CR, Couturier J et al. (2002) PRCC-TFE3 renal carcinomas. Morphologic, immunhistochemical, ultrastructural and molecular analysis of an entity associated with the t(X;1) (p11.2;q21). Am J Surg Pathol 26: 1553–1566

    Article  PubMed  Google Scholar 

  7. Atkins MB, Hidalgo M, Stadler WM et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909–918

    Article  PubMed  Google Scholar 

  8. Atzpodien J, Buer J, Sel S et al. (1999) Chemoimmuntherapie des fortgeschrittenen Nierenzellkarzinoms. Urologe A 38: 474–478

    Article  PubMed  Google Scholar 

  9. Atzpodien J, Kirchner H, Jonas U et al. (2004) Interleukin-2 and interferon alfa-2a based immunochemotherapy in advanced renal cell carcinoma: a prospective randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group. J Clin Oncol 22: 1174–1176

    Article  PubMed  Google Scholar 

  10. Atzpodien J, Schmitt E, Gertenbach U et al. (2005) Adjuvant treatment with Interleukin-2 and Interferon-α2a based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomized Trail of the German Cooperative Renal Carcinoma chemoimmunotherapy Group (DGCIN). Br J Cancer 92: 843–846

    Article  PubMed  Google Scholar 

  11. Bakal CW, Cynamon J, Lakritz PS, Sprayregen S (1993) Value of preoperative renal artery ambolization in reducing blood transfusion requirements during nephrectomy for renal cell carcinoma. J Vasc Interv Radiol 4: 727–731

    PubMed  Google Scholar 

  12. Baltarovich OH, Kurtz AB (1987) Sonographic evaluation of renal masses. Urol Radiol 9: 79–87

    PubMed  Google Scholar 

  13. Beare JB, McDonald JR (1949) Involvement of renal capsule in surgically removed hypernephroma: gross and histopathologic study. J Urol 61: 857

    Google Scholar 

  14. Becker N, Wahrendorf J (2006) Krebsatlas der Bundesrepublik Deutschland. dkfz, Heidelberg (http://www.dkfz-heidelberg.de)

  15. Becker F, Siemer S, Humke U et al. (2006) Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 Patients. Eur Urol 49: 308–313

    Article  PubMed  Google Scholar 

  16. Belardelli F, Ferrantini M, Parmiani G et al. (2004) International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 64: 6827–6830

    Article  PubMed  Google Scholar 

  17. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC et al. (2006) A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175: 57–62

    Article  PubMed  Google Scholar 

  18. Blom JH, van Poppel H, Marechal JM et al. (1999) Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. Eur Urol 36: 570–575

    Article  PubMed  Google Scholar 

  19. Bregni M, Dodero A, Peccatori J et al. (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99: 4234–4236

    Article  PubMed  Google Scholar 

  20. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin 2. Cancer 80: 1198–1220

    Article  PubMed  Google Scholar 

  21. Chan DY, Cadeddu JA, Jarrett TW et al. (2001) Laparoscopic radical nephrectomy: cancer control for renal cell carcinoma. J Urol 166: 2095–2100

    Article  PubMed  Google Scholar 

  22. Cheville JC, Blute Ml, Zincke H et al. (2001) Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 166: 453–456

    Article  PubMed  Google Scholar 

  23. Childs R, Chernoff A, Contentin N et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750–758

    Article  PubMed  Google Scholar 

  24. Chow WH, Gridley G, Fraumeni JF, Järvholm B (2000) Obesity, hypertension and the risk of kidney cancer in man. N Engl J Med 343: 1305–1311

    Article  PubMed  Google Scholar 

  25. Clark JI, Atkins MB, Urba WJ et al. (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21: 3133–3140

    Article  PubMed  Google Scholar 

  26. Cohen HT, McGovern FJ (2005) Renal-Cell Carcinoma. N Engl J Med 353: 2477–2490

    Article  PubMed  Google Scholar 

  27. Coppin C, Porszolt F, Awa A et al. (2005) Immunotherapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 25; CD001325

  28. Corica FA, Iczkowski KA, Cheng L et al. (1999) Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long term follow up. J Urol 161: 408–411

    Article  PubMed  Google Scholar 

  29. Dave DS, Lam JS, Leppert JT, Belldegrun AS (2005) Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. BJU Int 96: 1268–1274

    Article  PubMed  Google Scholar 

  30. Davis CJ, Mostofi FK, Sesterhenn IA (1995) Renal medullary carcinoma: a seventh sickle cell nephropathy. Am J Surg Pathol 19: 1–11

    PubMed  Google Scholar 

  31. Delahunt B, Thornton A (1996) Renal cell carcinoma. A historical perspective. J Urol Pathol 4: 31–39

    Google Scholar 

  32. Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunhistochemical study of 105 tumors. Mod Pathol 10: 537–544

    PubMed  Google Scholar 

  33. Delahunt B, Eble J (2005) History of the development of the classification of renal cell neoplasia. Clin Lab Med 25: 231–246

    Article  PubMed  Google Scholar 

  34. Deutsche Krebsgesellschaft (2002) AWMF Nierenzellkarzinom, AWMF Leitlinienregister Nr.032/037, 3. Aufl. Deutsche Krebsgesellschaft

  35. Dhote R, Pellicer-Coeuret M, Thiounn N et al. (2000) Risk factors for adult renal cell carcinoma: a systemic review and implications for prevention. BJU Int 86: 20–27

    Article  PubMed  Google Scholar 

  36. Dickinson WH (1885) On renal and urinary affections, vol. 3. Longmans Green, London

  37. Dillenburg W, Poulakis V, Skriapa K et al. (2006) Retroperitoneoscopic versus open surgical radical nephrectomy for large renal cell carcinoma in clinical stage cT2 or cT3a: Quality of life, pain and reconvalescence. Eur Urol 49: 314–323

    Article  PubMed  Google Scholar 

  38. Dos Santos R (1934) L’aortographie dans les tumeurs rénales et pararénales. Arch Mal Reins 8: 313

    Google Scholar 

  39. Dunn MD, Portis AJ, Shalhav AL et al. (2000) Laparoscopic versus open radical nephrectomy: a 9-year experience. J Urol 164: 1153–1159

    Article  PubMed  Google Scholar 

  40. Eble JN, Bonsib SM (1998) Extensively cystic renal neoplasms: cystic nephroma, cystic partially differentiated nephroblastoma, multilocular cystic renal cell carcinoma, cystic hamartoma of renal pelvis. Sem Diag Pathol 15: 2–20

    Google Scholar 

  41. Eble JN, Sauter G, Epstein JI et al. (2004) Pathology and genetics of tumours of the ruinary system and male genital organs.World Health Organization Classification of Tumours. IARC Press, Lyon

  42. Escudier B, Szcylik C, Eisen T et al. (2005) Randomised phase III trial of the raf kinase and VEGFR inhibitor sorafenib (Bay 43–9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 23: 4510

    Google Scholar 

  43. Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326: 1456–1463

    PubMed  Google Scholar 

  44. Fischedick AR, Peters PE, Kleinhans G, Pfeifer E (1987) Preoperative renal tumor embolization. A useful procedure? Acta Radiol 28: 303–306

    PubMed  Google Scholar 

  45. Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by Interferon alfa-2b compared with Interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–1659

    Article  PubMed  Google Scholar 

  46. Flanigan RC, Mickisch G, Sylvester R et al. (2004) Cytoreduktive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071–1076

    Article  PubMed  Google Scholar 

  47. Fornara P, doehn C, Seyfarth M, Joacham D (2000) Why is urological laparoscopy minimally invasive? Eur Urol 37: 241–250

    Article  Google Scholar 

  48. Fyfe G, Fisher RI, Rosenberg SA et al. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who receive high dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688–696

    PubMed  Google Scholar 

  49. George D, Michaelson D, Oh WK et al. (2003) Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22: 385

    Google Scholar 

  50. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. in Zusammenarbeit mit dem Robert Koch Institut Krebs in Deutschland (2006) Häufigkeiten und Trends, 5. überarbeitete Aufl. RO BO Print, Riegelsberg

  51. Gettman MT, Blute ML, Spotts B et al. (2001) Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 91: 354–361

    Article  PubMed  Google Scholar 

  52. Giberti C, Oneto F, Martorana G et al. (1997) Radical nephrectomy for renal cell carcinoma: long term results and prognostic factors on a series of 328 cases. Eur Urol 31: 40–48

    PubMed  Google Scholar 

  53. Gill IS, Matin SF, Desai MM et al. (2003) Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol 170: 64–68

    Article  PubMed  Google Scholar 

  54. Gill IS, Remer EM, Hasan WA et al. (2005) Renal cryoablation: outcome at 3 years. J Urol 173: 1903–1907

    Article  PubMed  Google Scholar 

  55. Gitlitz BJ, Figlin RA (2003) Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 30: 589–600

    Article  PubMed  Google Scholar 

  56. Gold PJ, Thompson JA, Markowitz DR et al. (1997) Metastatic renal cell carcinoma: Long-term survival after therapy with high dose continuous infusion interleukin-2. Cancer J Sci Am 3: 85–91

    Google Scholar 

  57. Grawitz P (1883) Die sogenannten Lipome der Niere. Arch Pathol Anat 93: 39

    Article  Google Scholar 

  58. Grawitz P (1884) Die Entstehung von Nierentumoren aus Nebennierengewebe. Verh Deutsch Ges Chir 13: 28

    Google Scholar 

  59. Grégoire R (1905) Procédé de néephrectomie pour cancer. Ann Mal Org Géen Urin 23: 179

    Google Scholar 

  60. Guinan P, Sobin LH, Algaba F et al. (1997) TNM staging of renal cell carcinoma. Cancer 80: 992–993

    Article  PubMed  Google Scholar 

  61. Guyon F (1881) Lecons cliniques sur les maladies des voies urinaires. J.B. Baillère, Paris

  62. Haferkamp A, Bastian PJ, Pritsch M et al. (2006) Prospective long term follow up of renal cell carcinomas with tumor thrombus extension into the vena cava. J Urol (in press)

  63. Hafez KS, Fergany AF, Novick AC (1999) Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162: 1930–1933

    Article  PubMed  Google Scholar 

  64. Hainsworth JD, Sosman JA, Spigel DR et al. (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889–7896

    Article  PubMed  Google Scholar 

  65. Han KR, Bui MH, Pantuck AJ et al. (2003) TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 169: 899–903

    Article  PubMed  Google Scholar 

  66. Hentschke P, Barkholt L, Uzunel M et al. (2003) Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31: 253–261

    Article  PubMed  Google Scholar 

  67. Herczel E (1890) Über Nierenextirpation. Beitr Klin Chir 6: 485

    Google Scholar 

  68. Herrlinger A, Schrott KM, Schott G, Sigel A (1991) What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 146: 1224–1227

    PubMed  Google Scholar 

  69. Heuser L, Friedman G, Modder U et al. (1977) CT Diagnose und Differentialdiagnose von Raumforderungen der Niere. Röntgenblätter 30: 479–489

  70. Holtl L, Zelle-Rieser C, Gander H et al. (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Can Res 8: 3369–3376

    Google Scholar 

  71. Hricak H, Williams RD (1984) Magnetic resonance imaging and its application in urology. Urology 23: 442–445

    PubMed  Google Scholar 

  72. Israel GM, Bosniak MA (2003) Renal inmaging for diagnosis and staging of renal cell carcinoma. Urol Clin North Am 30: 499–514

    Article  PubMed  Google Scholar 

  73. Itano NB, Blute ML, Spotts B, Zincke H (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164: 322–325

    Article  PubMed  Google Scholar 

  74. Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51: 203–205

    Article  PubMed  Google Scholar 

  75. Jocham D, Richter A, Hoffmann L et al. (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594–599

    Article  PubMed  Google Scholar 

  76. Judd ES, Hand JR (1929) Hypernephroma. J Urol 22: 10

    Google Scholar 

  77. Kalman D, Varenhorst E (1999) The role of arterial embolization in renal cell carcinoma. Scand J Urol Nephrol 33: 162–170

    Article  PubMed  Google Scholar 

  78. Kearney GP, Klein LA, Simon ML et al. (1975) B-mode nephrosonography in renal masses. Its use and some limitations. Urology 6: 125–129

    Article  PubMed  Google Scholar 

  79. Kennedy SM, Merino MJ, Linehan WM et al. (1990) Collecting duct carcinoma of the kidney. Hum Pathol 21: 449–456

    Article  PubMed  Google Scholar 

  80. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991–5004

    Article  PubMed  Google Scholar 

  81. Kinouchi T, Saiki S, Meguro N et al. (1999) Impact of tumor size on the clinical outcomes of patients with Robson Stage 1 renal cell carcinoma. Cancer 85: 689–695

    Article  PubMed  Google Scholar 

  82. Kovacs G, Akhtar M, Beckwith BJ et al. (1997) The heidelberg classification of renal cell tumors. J Pathol 183: 131–133

    Article  PubMed  Google Scholar 

  83. Kreiger N, Marrett LD, Dodds L et al. (1993) Risk factors for renal cell carcinoma: results of a population based case control study. Cancer Causes Cintrol 4: 101–110

    Article  Google Scholar 

  84. Lee CT, Katz J, Shi W et al. (2000) Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol 163: 730–736

    Article  PubMed  Google Scholar 

  85. Leibovich BC, Pantuck AJ, Bui MHT et al. (2003) Current staging of renal cell carcinoma. Urol Clin North Am 30: 481–497

    Article  PubMed  Google Scholar 

  86. Leibovich BC, Blute ML, Cheville JC et al. (2004) Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 171: 1066–1070

    Article  PubMed  Google Scholar 

  87. Lerner SE, Hawkins CA, Blute ML et al. (2002) Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing surgery. J Urol 167: 884–889

    PubMed  Google Scholar 

  88. Licht MR, Novick AC (1993) Nephron sparing surgery for renal cell carcinoma. J Urol 149: 1–7

    PubMed  Google Scholar 

  89. Lindor NM, Dechet CB, Greene MH et al. (2001) Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Gen Test 5: 101–106

    Article  Google Scholar 

  90. Lubarsch O (1894) Beiträge zur Histologie der von Nebennierenkeimen ausgehenden Nierengeschwülste. Arch Pathol Anat 135: 149

    Article  Google Scholar 

  91. Marten A, Flieger D, Renoth S et al. (2002) Therapeutic vaccination against metastatic renal cell carcinomaby autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 51: 637–644

    Article  PubMed  Google Scholar 

  92. McCredie M, Ford JM, Stewart JH (1988) Risk factors for cancer of renal parenchyma. Int J Cancer 42: 13–16

    PubMed  Google Scholar 

  93. McCredie M, Pommer W, McLaughlin JK et al. (1995) International renal-cell cancer study – analgetics. Int J Cancer 60: 345–349

    PubMed  Google Scholar 

  94. McDermott DF, Regan MM, Clark JI et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133–141

    Article  PubMed  Google Scholar 

  95. Medeiros LJ, Palmedo G, Krigman HR et al. (1999) Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am J Surg Pathol 23: 772–780

    Article  PubMed  Google Scholar 

  96. Medical Research Cuncil Renal Cancer Collaborators (1999) Interferon-alpa and survival in metastatic renal carcinoma: early results of randomised controlled trials. Lancet 353: 14–17

    Article  PubMed  Google Scholar 

  97. Mellemgaard A, Niwa S, Mehl ES et al. (1994) Risk factors for renal cell carcinoma in Denmark: Role of medication and medical history. Int J Epifemiol 23: 923–930

    Google Scholar 

  98. Mickisch G, Carballido J, Hellsten S et al. (2001) Guidelines on renal cell cancer. Eur Urol 40: 252–255

    Article  PubMed  Google Scholar 

  99. Mickisch GHJ, van Poppel H, de Prijck L et al. (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–970

    Article  PubMed  Google Scholar 

  100. Minasian LM, Motzer RJ, Gluck L et al. (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow up. J Clin Oncol 11: 1368–1375

    PubMed  Google Scholar 

  101. Minervini A, Lilas L, Morelli G et al. (2001) Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU Int 88: 169–172

    Article  PubMed  Google Scholar 

  102. Moch H, Gasser T, Amim MB et al. (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors. Cancer 89: 604–614

    Article  PubMed  Google Scholar 

  103. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408–417

    Article  PubMed  Google Scholar 

  104. Motzer RJ, Michaelson MD, Redman BG et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth facotr receptor and platelet-derived growth facotr receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24

    Article  PubMed  Google Scholar 

  105. Murphy LJT (1972) The history of urology. CC Thomas Books, Springfield, Ill.

  106. Negrier S, Escudier B, Lasset C et al. (1998) Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’immunotherapie. N Engl J Med 338: 1272–1278

    Article  PubMed  Google Scholar 

  107. Novick AC, Streem S, Montie JE et al. (1989) Conservative surgery for renal cell carcinoma: A single-center experience with 100 patients. J Urol 141: 835–839

    PubMed  Google Scholar 

  108. Oberling C, Riviere M, Haguenan F (1959) Ultrastructure of clear cell epitheliomas of the kidney (hypernephroma or Grawitz tumor) and ist implications for the histiogenesis of the tumors. Bull Cancer Assoc Franc 46: 356–358

    Google Scholar 

  109. Oh SW, Yoon YS, Sin SA (2005) Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea national health insurance corporation study. JCO 23: 4742–4754

    Article  Google Scholar 

  110. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. (2002) Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 25: 500–508

    Article  PubMed  Google Scholar 

  111. Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166: 1611–1623

    Article  PubMed  Google Scholar 

  112. Pantuck AJ, Zisman A, Dorey F et al. (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169: 2076–2083

    Article  PubMed  Google Scholar 

  113. Parwani AV, Husain An, Epstein JI et al. (2001) Low grade myxoid renal epithelial neoplasms with distal nephron differentiation. Hum Pathol 32: 506–512

    Article  PubMed  Google Scholar 

  114. Pedrazzoli P, Da Prada GA, Giorgiani G et al. (2002) Allogeneic blood stem cell transplantation after a reduced-intensity preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94: 2409–2415

    Article  PubMed  Google Scholar 

  115. Peters C, Brown GL (1980) The role of lymphadenectomy in the management of renal cell carcinoma. Urol Clin North Am 7: 705–709

    PubMed  Google Scholar 

  116. Pischon T, Lahmann PH, Boeing H et al. (2006) Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 118: 728–738

    Article  PubMed  Google Scholar 

  117. Quesada JR, Swanson DA, Gutterman JU (1985) Phase II study of interferon alpha in metastatic renal cell carcinoma: a progress report. J Clin Oncol 3: 1086–1092

    PubMed  Google Scholar 

  118. Ramani AP, Desai MM, Steinberg AP et al. (2005) Complications of laparoscopic partial nephrectomy in 200 cases. J Urol 173: 42–47

    PubMed  Google Scholar 

  119. Rayer PFO (1837) Traité des Maladies des Reins. Paris 1837–1841

  120. Rini BI, Zimmerman T, Stadler WM et al. (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20: 2017–2024

    Article  PubMed  Google Scholar 

  121. Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028–1043

    Article  PubMed  Google Scholar 

  122. Robin C (1855) Memoire sur l’épitelioma du rein. Gaz Hop 28: 186–194

    Google Scholar 

  123. Robson CJ, Churchill BM, Anderson W (1969) Results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301

    PubMed  Google Scholar 

  124. Rohde D (2005) Studienlandschaft Nierenzellkarzinom. Medikamentöse Therapie. Urologe 44: 1423–1429

    Article  PubMed  Google Scholar 

  125. Schlehofer B, Heuer C, Blettner M et al. (1995) Occupation, smoking and demographic factors and renal cell carcinoma in Germany. Int J Epidemiol 24: 51–57

    PubMed  Google Scholar 

  126. Schlehofer B, Pommer W, Mellemgaard A et al. (1996) International renal cell cancer study – VI role of medical and family history. Int J Cancer 66: 723–726

    Article  PubMed  Google Scholar 

  127. Semb C (1954) Carcinoma of the solitary kidney treated by partial resection: three years observation. Urologia 21: 155

    Google Scholar 

  128. Semelka RC, Shoenhut JP, Margo CM et al. (1993) Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imag 3: 597–602

    Google Scholar 

  129. Shvarts O, Lam JS, Kim HL, Belldegrun AS (2005) Staging of renal cell carcinoma: current concepts. BJU Int 95(Suppl 2): 8–13

    Google Scholar 

  130. Siemer S, Lehmann J, Kamradt J et al. (2004) Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol 171: 2155–2159

    Article  PubMed  Google Scholar 

  131. Siemer S, Lehmann J, Loch A et al. (2005) Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173: 33–37

    PubMed  Google Scholar 

  132. Siminovitch JP, Montie JE, Straffon RA (1982) Lymphadenectomy in renal adenocarcinoma. J Urol 127: 1090–1091

    PubMed  Google Scholar 

  133. Stetter R (1887) Demonstration eines extirpierten Pyloruscarcinoms und einer extirpierten carcinomatösen Niere. Verh Dtsch Ges Chir 16: 36

    Google Scholar 

  134. Stoddard CL (1861) Case of encephaloid disease of kidney, removal. Med Surg Reporter 7: 126

    Google Scholar 

  135. Stolle CA, Glenn G, Zbar B et al. (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation 12: 417–423

    Article  PubMed  Google Scholar 

  136. Störkel S, Eble JN, Adlakha K et al. (1997) Classification of renal cell carcinoma. Cancer 80: 987–989

    Article  PubMed  Google Scholar 

  137. Studer UE, Scherz S, Scheidegger J et al. (1990) Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 144: 243–245

    PubMed  Google Scholar 

  138. Swanson DA, Orovan WL, Johnson DE, Giacco G (1981) Osseous metastasis secondary to renal cell carcinoma. Urology 18: 556–561

    Article  PubMed  Google Scholar 

  139. Swick M (1929) Darstellung der Niere und Harnwege im Röntgenbild durch intravenöse Einbringung eines neuen Kontraststoffes, des Uroselectans. Klin Wochenschr 8: 2087–2089

    Article  Google Scholar 

  140. Targonski PV, Frank W, Stuhldreher D et al. (1994) Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes, and metastases stage 1 and stage 2 patients. J Urol 152: 1389–1392

    PubMed  Google Scholar 

  141. Terronea C, Craccoa C, Porpigliaa F et al. (2006) Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49: 324–331

    Article  PubMed  Google Scholar 

  142. Thompson RH, Cheville JC, Lohse CM et al. (2005) Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 104: 53–60

    Article  PubMed  Google Scholar 

  143. Tsui KH, Shvarts O, Smith RB et al. (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163: 1090–1095

    Article  PubMed  Google Scholar 

  144. Uchida M, Imaide Y, Sugimoto K et al. (1995) Percutaneous cryosurgery for renal tumors. Br J Urol 75: 132–136

    PubMed  Google Scholar 

  145. Ueno NT, Cheng YC, Rondon G et al. (2003) Rapid induction of complete donor chimerism by the use of a reduced intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102: 3829–3836

    Article  PubMed  Google Scholar 

  146. Umeda T, Miijima T (1986) Phase II study of alpha interferon on renal cell carcinoma: summary of three collaborative trials. Cancer 58: 1231–1235

    Article  PubMed  Google Scholar 

  147. Van Herpen CM, De Mulder PH (2002) Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Crit Rev Oncol Hematol 41: 327–334

    PubMed  Google Scholar 

  148. Van Spronsen DJ, de Weijer KJM, Mulders PFA, De Mulder PHM (2005) Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti Cancer Drugs 16: 709–717

    Article  PubMed  Google Scholar 

  149. Vieweg J, Jackson A (2004) Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin Biol Ther 4: 1791–1801

    Article  PubMed  Google Scholar 

  150. Voelcker F, von Lichtenberg A (1906) Roentgenographie des Nierenbeckens nach Kollargolfüllung. Münch Med Wochenschr 53: 105–107

    Google Scholar 

  151. Volm M, Kastel M, Mattern J, Efferth T (1993) Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in ranl cell carcinomas. Cancer 7: 3981–3987

    Article  Google Scholar 

  152. Von Lichtenberg A, Swick M (1929) Klinische Prüfung des Uroselectans. Klein Wochenschr 8: 2089–2091

    Article  Google Scholar 

  153. Wade H (1935) Renal tumors. Aust NZ J Surg 5: 3–17

    Google Scholar 

  154. Wagner FB (1946) Arteriography in renal diagnosis: Preliminary report and critical evaluation. J Urol 56: 625

    Google Scholar 

  155. Waldeyer W (1867) Zur Entwicklung von Karzinomen. Arch Pathol Anat Physiol Klein Med 41: 470–523

    Article  Google Scholar 

  156. Wille AH, Roigas J, Deger S et al. (2004) Laparoscopic nephrectomy: techniques, results and oncological outcome in 125 consecutive cases. Eur Urol 45: 483–489

    Article  PubMed  Google Scholar 

  157. Wittekind C, Meyer HJ, Bootz F (2003) TNM Klassifikation maligner Tumoren, 6. Aufl. Springer, Berlin Heidelberg New York

  158. Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434

    Article  Google Scholar 

  159. Zincke H, Engen DE, Henning KM, McDonald MW (1985) Treatment of renal cell carcinoma by in situ partial nephrectomy and extracorporeal operation with autotransplantation. May Clin Proc 60: 651

    Google Scholar 

  160. Zisman A, Pantuck A, Chao D et al. (2001) Reevaluation of the 1997 TNM classification for renal carcinoma T1 and T2 cutoff point at 4.5 rather than 7 cm correlates better with clinical outcome. J Urol 166: 54–58

    Article  PubMed  Google Scholar 

  161. Zisman A, Wieder JA, Pantuck AJ et al. (2003) Renal cell carcinoma with tumor thrombus extension: Biology, role of nephrectomy and response to immunotherapy. J Urol 169: 909–916

    Article  PubMed  Google Scholar 

  162. Zlotta AR, Wildschutz T, Raviv G et al. (1997) Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol 11: 251–258

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Urologische Klinik, Klinikum, Darmstadt

    D. Rohde

  2. Urologische Klinik und Poliklinik, Universitätsklinikum, Bonn

    S. C. Müller

  3. Urologische Klinik und Poliklinik, Universitätsklinikum, Essen

    H. Rübben

  4. Klinik für Urologie, Universitätsklinikum, Im Neuenheimer Feld 110, 69120, Heidelberg

    A. Haferkamp & M. Hohenfellner

Authors
  1. A. Haferkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. C. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Hohenfellner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Haferkamp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haferkamp, A., Rohde, D., Müller, S.C. et al. Das Nierenzellkarzinom. Urologe 45 (Suppl 4), 74–84 (2006). https://doi.org/10.1007/s00120-006-1136-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1136-1

Schlüsselwörter

Search

Navigation